AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18760153 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Research Arm Test (ARAT) (affected nondominant side)
Number of subjects: 52
Study 18760153 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) function score (affected dominant side)
Number of subjects: 52
Study 18760153 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) function score (affected nondominant side)
Number of subjects: 52
Study 18760153 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Activity Log (MAL) quality of movement score (affected dominant side)
Number of subjects: 52
Study 18760153 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Activity Log (MAL) quality of movement score (affected nondominant side)
Number of subjects: 52
Study 18760153 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite upper‐extremity strength (affected dominant side)
Number of subjects: 52
Study 18760153 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) time score (affected nondominant side)
Number of subjects: 52
Study 18760153 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of upper‐extremity use (both affected sides)
Number of subjects: 52
Study 16018819 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 56
Study 16018819 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon GV
Number of subjects: 56
Study 16018819 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon 5
Number of subjects: 56
Study 12821556 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU and Vitamin C 1 g before supper
Number of subjects: 11
Study 12821556 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU and Vitamin C 1 g before breakfast
Number of subjects: 11
Study 12821556 — intervention group
Group type: COMPARATOR
Intervention: No vitamins, no test meal
Number of subjects: 11
Study 12821556 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU and Vitamin C 1 g (timing not specified)
Number of subjects: 11
Study 10591717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home
Number of subjects: 199
Study 10591717 — intervention group
Group type: COMPARATOR
Intervention: Hospital inpatient care
Number of subjects: 199
Study 8929748 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol controlled release tablet (100 mg)
Number of subjects: 12
Study 8929748 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol normal release tablet (10 mg)
Number of subjects: 12
Study 1899447 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ribose (3.3 mg/kg/min x 30 min)
Number of subjects: 17
Study 1899447 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 17
Study 6405608 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrogen diet (364 mg/kg . day)
Number of subjects: 10
Study 6405608 — intervention group
Group type: COMPARATOR
Intervention: Low nitrogen diet (180 mg/kg . day)
Number of subjects: 10
Study 6405608 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 10
Study 31032879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 514
Study 31032879 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 514
Study 29556759 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective lipofilling
Number of subjects: 15
Study 29556759 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PMRT)
Number of subjects: 15
Study 25648870 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPS method
Number of subjects: 40
Study 25648870 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional technique)
Number of subjects: 40
Study 24766975 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Number of subjects: 7500
Study 24766975 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7500
Study 22295066 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask and hand hygiene
Number of subjects: 1178
Study 22295066 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask only
Number of subjects: 1178
Study 22295066 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1178
Study 20861631 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid etching treatment (E)
Number of subjects: 28
Study 20861631 — intervention group
Group type: COMPARATOR
Intervention: No acid etching treatment (NE)
Number of subjects: 28
Study 17996549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation directed at the C3 through C4 level
Number of subjects: 72
Study 17996549 — intervention group
Group type: COMPARATOR
Intervention: Sham manual procedure (placebo)
Number of subjects: 72
Study 15896425 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole formula diet based on lyophilised foods (Treatment Group)
Number of subjects: 53
Study 15896425 — intervention group
Group type: COMPARATOR
Intervention: Nutritional advice (Control Group)
Number of subjects: 53
Study 11952435 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg/kg clonidine
Number of subjects: 105
Study 11952435 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 microg/kg clonidine
Number of subjects: 105
Study 11952435 — intervention group
Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 105
Study 9892471 — intervention group
Group type: EXPERIMENTAL
Intervention: InteliSite capsule activated in the jejunum
Number of subjects: 8
Study 9892471 — intervention group
Group type: EXPERIMENTAL
Intervention: InteliSite capsule activated in the ileum
Number of subjects: 8
Study 9892471 — intervention group
Group type: EXPERIMENTAL
Intervention: InteliSite capsule activated in the colon
Number of subjects: 8
Study 7649751 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite model of hospital motivations for MRI adoption
Number of subjects: 507
Study 7649751 — intervention group
Group type: COMPARATOR
Intervention: Individual models (profit maximization, technological preeminence, clinical excellence)
Number of subjects: 507
Study 7649751 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite model
Number of subjects: 507
Study 2228036 — intervention group
Group type: EXPERIMENTAL
Intervention: NOR 400 mg t.i.d. for 10 days
Number of subjects: 37
Study 2228036 — intervention group
Group type: EXPERIMENTAL
Intervention: NOR 800 mg b.i.d. for 10 days
Number of subjects: 37
Study 84532 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected environment-prophylactic antibiotic (PEPA) program
Number of subjects: 58
Study 84532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PEPA program)
Number of subjects: 58
Study 31145185 — intervention group
Group type: EXPERIMENTAL
Intervention: Reengineered Discharge (RED) implementation in Standard SNFs
Number of subjects: 4
Study 31145185 — intervention group
Group type: COMPARATOR
Intervention: Reengineered Discharge (RED) implementation in Enhanced SNFs
Number of subjects: 4
Study 30666480 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) with Ketac Molar Easymix® (3 M ESPE)
Number of subjects: 25
Study 30666480 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) with Vitro Molar® (DFL)
Number of subjects: 25
Study 28253943 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with patellar resurfacing (TKAPR)
Number of subjects: 60
Study 28253943 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty without patellar resurfacing (TKA)
Number of subjects: 60
Study 25338777 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 23
Study 25338777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 25607554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg daily for up to 24 weeks
Number of subjects: 596
Study 25607554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study 21537940 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole monotherapy (200 mg/day)
Number of subjects: 20
Study 21537940 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (20 mg/day)
Number of subjects: 20
Study 19827462 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Feeding (IF): CHO-PRO solution (1.2 g CHO/kg BM and 0.4 g PRO/kg BM) immediately postexercise
Number of subjects: 9
Study 19827462 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Feeding (DF): Water immediately postexercise, CHO-PRO solution 1 hr postexercise
Number of subjects: 9
Study 19827462 — intervention group
Group type: COMPARATOR
Intervention: Control (CON): Water (12 ml/kg BM) immediately and 1 hr postexercise
Number of subjects: 9
Study 18225472 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice 'case-management model' multifactorial intervention
Number of subjects: 45
Study 18225472 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 15159476 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) supplementation (about 0.10 g/kg/day) for 4 months
Number of subjects: 30
Study 15159476 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 30
Study 15159476 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) supplementation
Number of subjects: 30
Study 15159476 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid use
Number of subjects: 30
Study 12238654 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-1
Number of subjects: 4412
Study 12238654 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2
Number of subjects: 4412
Study 12238654 — intervention group
Group type: EXPERIMENTAL
Intervention: Age distribution
Number of subjects: 4412
Study 12238654 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 4412
Study 12238654 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 4412
Study 12238654 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical disparities
Number of subjects: 4412
Study 9853540 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (1.3 g/day of soluble fiber)
Number of subjects: 66
Study 9853540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran (2.6 g/day of soluble fiber)
Number of subjects: 66
Study 9853540 — intervention group
Group type: COMPARATOR
Intervention: Control (cookies with wheat bran)
Number of subjects: 66
Study 8299777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IV Ig) 500 mg/kg per month
Number of subjects: 27
Study 8299777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 27
Study 8299777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IV Ig)
Number of subjects: 27
Study 2925707 — intervention group
Group type: EXPERIMENTAL
Intervention: Long thumb-spica cast
Number of subjects: 51
Study 2925707 — intervention group
Group type: COMPARATOR
Intervention: Short thumb-spica cast
Number of subjects: 51
Study 29967373 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary-type SOD patients undergoing ERCP
Number of subjects: 60
Study 29967373 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile duct diameter ≥12 mm
Number of subjects: 60
Study 29967373 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 60
Study 29967373 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 60
Study 26996196 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU
Number of subjects: 56
Study 26996196 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 56
Study 23669452 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led tactile stimulation (rubbing the ipsilateral thigh distal to the site for 15 seconds before, during, and after injections)
Number of subjects: 120
Study 23669452 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led tactile stimulation
Number of subjects: 120
Study 23537313 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly (W) schedule with gemcitabine 1000 mg/m2 Day 1,8 + docetaxel 75 mg/m2 Day 1 q3W
Number of subjects: 241
Study 23537313 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly (3 W) schedule with gemcitabine 1000 mg/m2 Day 1,8 + docetaxel 75 mg/m2 Day 1 q3W
Number of subjects: 241
Study 23537313 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly (W) schedule with gemcitabine 1250 mg/m2 Day 1,8 + paclitaxel 175 mg/m2 Day 1 q3W
Number of subjects: 241
Study 23537313 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly (3 W) schedule with gemcitabine 1250 mg/m2 Day 1,8 + paclitaxel 175 mg/m2 Day 1 q3W
Number of subjects: 241
Study 23537313 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly (W) schedule with gemcitabine 800 mg/m2 Day 1,8,15 + docetaxel 30 mg/m2 Day 1,8,15 q4W
Number of subjects: 241
Study 23537313 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly (3 W) schedule with gemcitabine 800 mg/m2 Day 1,8,15 + docetaxel 30 mg/m2 Day 1,8,15 q4W
Number of subjects: 241
Study 23537313 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly (W) schedule with gemcitabine 800 mg/m2 Day 1,15 + paclitaxel 80 mg/m2 Day 1,8,15 q4W
Number of subjects: 241
Study 23537313 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly (3 W) schedule with gemcitabine 800 mg/m2 Day 1,15 + paclitaxel 80 mg/m2 Day 1,8,15 q4W
Number of subjects: 241
Study 20518265 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnett-Macků technique of anterior vaginal plastic surgery (BM; n=18)
Number of subjects: 87
Study 20518265 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior plastic surgery with individualized mesh (Mesh; n=33)
Number of subjects: 87
Study 20518265 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolift with pre-set standard-size mesh (Prolift; n=36)
Number of subjects: 87
Study 20518265 — intervention group
Group type: COMPARATOR
Intervention: Post-operative assessment
Number of subjects: 87
Study 20518265 — intervention group
Group type: COMPARATOR
Intervention: Post-operative assessment for urge
Number of subjects: 87
Study 18533063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol plus remifentanil (TR)
Number of subjects: 62
Study 18533063 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (T)
Number of subjects: 62
Study 16612557 — intervention group
Group type: EXPERIMENTAL
Intervention: Replanted fingers
Number of subjects: 20
Study 16612557 — intervention group
Group type: COMPARATOR
Intervention: Normal fingers (control)
Number of subjects: 20
Study 14585013 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous cuing with spread attention
Number of subjects: 0
Study 14585013 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous cuing with focused attention
Number of subjects: 0
Study 14585013 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous cuing with spread attention
Number of subjects: 0
Study 14585013 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous cuing with focused attention
Number of subjects: 0
Study 11692899 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (0.75 mg/kg for six months)
Number of subjects: 19
Study 11692899 — intervention group
Group type: COMPARATOR
Intervention: Vitamin (control group)
Number of subjects: 19
Study 9398956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 100 mg
Number of subjects: 374
Study 9398956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 200 mg
Number of subjects: 374
Study 9398956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 8199107 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal intraocular lenses (3M design)
Number of subjects: 33
Study 8199107 — intervention group
Group type: COMPARATOR
Intervention: Monofocal intraocular lenses (all polymethylmethacrylate biconvex, 6 mm optical diameter)
Number of subjects: 33
Study 8199107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic visual acuity
Number of subjects: 33
Study 3296260 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 80
Study 3296260 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with irradiation
Number of subjects: 80
Study 3296260 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 80
Study 3296260 — intervention group
Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 80
Study 31639232 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorder symptoms (high severity, SCOFF score of 5)
Number of subjects: 71712
Study 31639232 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorder symptoms (subthreshold levels)
Number of subjects: 71712
Study 31639232 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorder presentations that included purging
Number of subjects: 71712
Study 31639232 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginalized backgrounds (gender and sexual minorities)
Number of subjects: 71712
Study 29466268 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive calisthenic push-up training (PUSH)
Number of subjects: 23
Study 29466268 — intervention group
Group type: COMPARATOR
Intervention: Traditional bench press training (BENCH)
Number of subjects: 23
Study 27910037 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Charcoal (AC) administered at 2 hours post-dose
Number of subjects: 12
Study 27910037 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Charcoal (AC) administered at 5 hours post-dose
Number of subjects: 12
Study 27910037 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Charcoal (AC) administered at 8 hours post-dose
Number of subjects: 12
Study 27910037 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban administered alone
Number of subjects: 12
Study 25073037 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group (real-time monitoring for HHV-6 and HHV-7 viremia)
Number of subjects: 129
Study 25073037 — intervention group
Group type: COMPARATOR
Intervention: No-monitoring group (usual care)
Number of subjects: 129
Study 25073037 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group
Number of subjects: 129
Study 22260882 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based cooperative learning
Number of subjects: 98
Study 22260882 — intervention group
Group type: COMPARATOR
Intervention: Technology-based individual learning
Number of subjects: 98
Study 21244568 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope(®) videolaryngoscopy (GV)
Number of subjects: 80
Study 21244568 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 80
Study 18458145 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 461
Study 18458145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study 16504078 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction manipulation (DM) and neural mobilization (NM)
Number of subjects: 55
Study 14660270 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept therapy
Number of subjects: 0
Study 10856099 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific dosage and duration not mentioned)
Number of subjects: 300
Study 9357487 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycodot test for tuberculosis
Number of subjects: 52
Study 9357487 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycodot test for tuberculosis in HIV-negative patients
Number of subjects: 52
Study 9357487 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycodot test for tuberculosis in HIV-positive patients
Number of subjects: 52
Study 9357487 — intervention group
Group type: COMPARATOR
Intervention: Control sera from patients with acute non-tuberculous lobar pneumonia
Number of subjects: 52
Study 9357487 — intervention group
Group type: COMPARATOR
Intervention: Control sera from patients with no respiratory disease
Number of subjects: 52
Study 31816352 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid)
Number of subjects: 0
Study 31816352 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs) with water-insoluble radiolabel (technetium-99 m-labeled ion exchange resin)
Number of subjects: 0
Study 31816352 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid) without water ingestion
Number of subjects: 0
Study 31816352 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid) with water ingestion
Number of subjects: 0
Study 29422021 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-theoretic value of information (VOI) method for optimal sample size and significance level in RCTs
Number of subjects: 0
Study 29422021 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-theoretic VOI methods
Number of subjects: 0
Study 27568219 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer reconstruction
Number of subjects: 58
Study 27568219 — intervention group
Group type: COMPARATOR
Intervention: Single-layer reconstruction
Number of subjects: 58
Study 24425854 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily irrigation with sterile saline solution during silicone hydrogel contact lens continuous wear.
Number of subjects: 161
Study 24425854 — intervention group
Group type: COMPARATOR
Intervention: Control group (no irrigation).
Number of subjects: 161
Study 23218158 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive oral ziprasidone
Number of subjects: 504
Study 23218158 — intervention group
Group type: COMPARATOR
Intervention: Control group (lithium or divalproex)
Number of subjects: 504
Study 19769420 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride
Number of subjects: 0
Study 19769420 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 16792536 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon-alpha-2a (40 kDa) plus ribavirin
Number of subjects: 64
Study 15321956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic nCPAP
Number of subjects: 230
Study 15321956 — intervention group
Group type: COMPARATOR
Intervention: Rescue nCPAP
Number of subjects: 230